Additional beneficial effects of recombinant growth hormone in alendronate-treated patients with idiopathic osteoporosis

Endocrine Journal

Volumn 56, Issue 7, 2009, Pages 851-858

  Lopes, Renata Francioni ^a   Coeli, Cláudia Medina ^a   Vaisman, Mario ^a   De Farias, Maria Lucia Fleiuss ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Alendronate; Bone mineral density; Growth hormone; Idiopathic osteoporosis; IGF 1

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIUM CARBONATE; HUMAN GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; IDIOPATHIC OSTEOPOROSIS; LUMBAR SPINE; MALE;

ABSORPTIOMETRY, PHOTON; ADULT; ALENDRONATE; ALKALINE PHOSPHATASE; BONE DENSITY CONSERVATION AGENTS; CALCIUM; COLLAGEN TYPE I; DRUG THERAPY, COMBINATION; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDES; RECOMBINANT PROTEINS; VITAMIN D;

EID: 70350645298     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K09E-048     Document Type: Article

References (35)

1. Soyka LA, Fairfield WP, Klibanski A (2000) Hormonal determinants and disorders of peak bone mass in children. J Clin Endocrinol Metab 85: 3951-3963
2. Pietschmann P, Kudlacek S, Grisar J, et al. (2001) Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest 31: 444-451. (Pubitemid 32479208)
3. Kurland ES, Chan FKW, Rosen CJ, Bilezikian JP (1998) Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 83: 2576-2579.
4. Ljunghall S, Johannsson AG, Burman P, Kampe O, Lindh E, Karlsson FA (1992) Low plasma levels of IGF-1 in male patients with idiopathic osteoporosis. J Intern Med 232: 59-64.
5. Reed BY, Zerwekh JE, Sakhaee K, Breslau NA, Gorrschalk F, Pak CYC (1995) Serum IGF-1 is low and correlated with osteoblastic surface in idiopathic osteoporosis. J Bone Miner Res 10: 1218-1224.
6. Khosla S (1997) Editorial: Idiopathic osteoporosis - is the osteoblast to blame? J Clin Endocrinol Metab 82: 2792-2794.
7. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY (1998) Association between serum insulin-growth-factor 1 (IGF-1) and a simple repeat in IGF-1 gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 83: 2286-2290. (Pubitemid 28503015)
8. Rivadeneira F, Houwing-Duistermaat J, Pols HA, Van Dujin CM, Uitterlinden AG (2002) Insulin-like-growth-factor 1 (IGF-1) gene promoter polymorphism and the risk of fracture in the elderly: The Rotterdam study. J Bone Miner Res 17:S 177.
9. Janssen YJH, Hamdy NAT, Frohlich M, Roelfsema F (1998) Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 83: 2143-2148.
10. Rosen CJ, Bilezikian JP. Anabolic therapy for osteoporosis (2001) J Clin Endocrinol Metab 86: 957-964.
11. Nilsson AG (2000) Effects of growth hormone replacement therapy on bone markers and bone mineral density in growth hormone-deficient adults. Horm Res 54: 52-57.
12. Stabnov L, Kasukawa Y, Guo R, et al. (2002) Effect of insulin-like growth factor-1 (IGF-1) plus alendronate on bone density during puberty in IGF-1-deficient MIDI mice. Bone 30: 909-916. (Pubitemid 34616022)
13. Biermansz NR, Hamdy NAT, Janssen YJH, Roelfsema F (2001) Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy randomized controlled trial. J Clin Endocrinol Metab 86: 3079-3085.
14. Liberman UA, Weiss SR, Broll J, et al. (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333: 1437-1443.
15. Bone HG, Hosking D, Devogelaer JP, et al. (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189-1199. (Pubitemid 38339363)
16. Smith MR, McGovern FJ, Zietman AL, et al. (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345: 948-955. (Pubitemid 34940810)
17. th ed. Washington D.C. 370-379.
18. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339: 292-299. (Pubitemid 28366417)
19. Kassem M, Blum W, Risteli J, Mosekilde L, Eriksen EF (1993) Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro. Calcif Tissue Int 52: 222-226. (Pubitemid 23090716)
20. Biller BMK, Sesmilo G, Baum HBA, Hayden D, Schoenfeld D, Klibanski A (2000) Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult onset GH-deficiency. J Clin Endocrinol Metab 85: 970-976.
21. Conceição FL, Boguszewski CL, Meister LHF, et al. (2003) Deficiência de GH em adultos: Resultados do Estudo Multicêntrico Brasileiro. Arq Bras Endocrinol Metab 47: 312-322.
22. Johannsson AG, Rosen T, Bosaeus I, Sjostrom L, Bengtsson B-A (1996) Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 81: 2865-2873 (Pubitemid 26323877)
23. Valimaki MJ, Salmela PI, Salmi J, et al. (1999) Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur J Endocrinol 140: 545-554. (Pubitemid 29314717)
24. Golden NH, Kreitzer P, Jacobson MS, et al. (1994) Disturbances in growth hormone secretion and action in adolescents with anorexia nervosa. J Pediatr 125: 655-660. (Pubitemid 24318447)
25. Sugimoto T, Nakaoka D, Nasu M, Kanzawa M, Sugishita T, Chihara K (1999) Effect of recombinant human growth hormone in elderly osteoporotic women. Clin Endocrinol (Oxf) 51: 715-724. (Pubitemid 30050821)
26. Gillberg P, Mallmin H, Petren-Mallmin M, Lunghall S, Nilsson AG (2002) Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab 87: 4900-4906. (Pubitemid 35331061)
27. Johannsson AG, Lindh E, Blum WF, Kollerup G, Sorensen OH, Ljunghall S (1996) Effects of growth hormone and insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 81: 44-48. (Pubitemid 26035002)
28. Kann P, Piepkorn B, Schehler B, et al (1998) Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol (Oxf) 48: 561-568. (Pubitemid 28252992)
29. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA (1997) Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 82: 550-555. (Pubitemid 27068627)
30. Johannsson AG, Eden Engstrom B, Ljunghall S, Karlsson FA, Burman P (1999) Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab 84: 2002-2007. (Pubitemid 30647025)
31. Riggs BL, Khosla S, Melton III LJ (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23: 279-302. (Pubitemid 34651948)
32. Christmas C, O'Connor KG, Harman SM, et al. (2002) Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy aged women and men. J Gerontology 57: 12-18. (Pubitemid 34074441)
33. van der Klaauw AA, Biermasz NR, Zelissen PMJ, et al. (2007) Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism. Eur J Endocrinol 157: 709-716.
34. Duschek EJJ, Gooren LJ, Netelenbos C (2005) Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3. Maturitas 51: 286-293.
35. Bravenboer N, Holzmann P, de Boer H, Roos JC, Van der Veen EA, Lips P (1997) The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men. J Clin Endocrinol Metab 82: 1818-1822. (Pubitemid 127495193)